Table 2.
Distribution of ESBL-producing strains in China during 2016–2017
| IAI (n=2,546) | UTI (n=1,947) | Total (n=4,493) | ||||
|---|---|---|---|---|---|---|
| HA (n=2,076) | CA (n=455)* | HA (n=1,381) | CA (n=561)* | HA (n=3,457) | CA (n=1,016)* | |
| Total ESBL + (% of HA or CA) | 557 (26.8) | 116 (25.5) | 478 (34.6) | 204 (36.4) | 1035 (29.9) | 320 (31.5) |
| E. coli | 845 (40.7) | 224 (49.2) | 815 (59.0) | 361 (64.3) | 1660 (48.0) | 585 (57.6) |
| ESBL + (% of E. coli HA or CA) | 437(51.7)# | 95 (42.4) | 378 (46.4) | 176 (48.8) | 815 (49.1) | 271 (46.3) |
| K. pneumoniae | 454 (21.9) | 97 (21.3) | 239 (17.3) | 71 (12.7) | 693 (20.9) | 168 (16.5) |
| ESBL + (% of K. pneumoniae HA or CA) | 100 (22.0)& | 20 (20.6) | 86 (36.0) | 23 (32.4) | 186 (26.8) | 43 (25.6) |
| P. mirabilis | 36 (1.7) | 8 (1.8) | 33 (2.4) | 22 (3.9) | 69 (2.0) | 30 (3.0) |
| ESBL + (% of P. mirabilis HA or CA) | 13 (36.1) | 0 (0) | 10 (30.3) | 5 (22.7) | 23 (33.3) | 5 (16.7) |
| K. oxytoca | 30 (1.4) | 7 (1.5) | 8 (0.6) | 4 (0.7) | 38 (1.1) | 11 (1.1) |
| ESBL + (% of K. oxytoca HA or CA) | 7 (23.3) | 1 (14.3) | 4 (50) | 0 (0) | 11 (28.9) | 1 (9.1) |
Notes: *Missing isolates are those whose hospitalization was not specified. #P=0.016 (IAI HA vs CA); &P<0.001 (IAI HA vs UTI HA).
Abbreviations: HA, hospital-acquired; CA, community-acquired; IAI, intraabdominalinfection; UTI, urinary tract infection; IPM, Carbapenems: Imipenem; ETP, Ertapenem; AMK, Aminoglycoside: Amikacin; TZP, Piperacillin-Tazobactam; FOX, Cephalosporins: Cefoxitin; CAZ, Ceftazidime; CRO, Ceftriaxone; CTX, Cefotaxime; FEP, Cefepime; LVX, Fluoroquinolones: Levofloxacin; CIP, Ciprofloxacin.